Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in ¹¹C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer.

ABSTRACT:

Purpose

Outcomes for resistant metastatic castration-resistant prostate cancer (CRPC) are poor. Stereotactic ablative radiotherapy (SABR) induces antitumor immunity in clinical and preclinical studies, but immunologic biomarkers are lacking.

Patients and methods

Eighty-nine patients with oligometastatic CRPC were identified by ¹¹C-Choline-PET (Choline-PET) from August 2016 to December 2019 and treated with SABR. Prespecified coprimary endpoints were 2-year overall survival (OS) and PSA progression. Secondary endpoints included 2-year SABR-treated local failure and 6-month adverse events. Correlative studies included peripheral blood T-cell subpopulations before and after SABR.

Results

128 lesions in 89 patients were included in this analysis. Median OS was

SUBMITTER: Zhang H 

PROVIDER: S-EPMC8639778 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature